Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: Application to brain and plasma from rats with ischemic stroke

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Hawkins, Kimberly E ^a   Demars, Kelly M ^a   Yang, Changjun ^a   Rosenberg, Gary A ^b   Candelario Jalil, Eduardo ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Fluorescence resonance energy transfer peptide; Focal cerebral ischemia; Immunocapture assay; Matrix metalloproteinase 9 activity

Indexed keywords

ENZYME ANTIBODY; GELATINASE B;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HOMOGENATE; BRAIN ISCHEMIA; CELL LYSATE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BINDING; ENZYME BLOOD LEVEL; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; ZYMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; BRAIN ISCHEMIA; ENZYME ASSAYS; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; GELATIN; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; PEPTIDES; PROTEIN BINDING; RATS; RATS, WISTAR; STROKE;

RATTUS;

EID: 84875203698     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-14     Document Type: Article

References (61)

1. Matrix metalloproteinases. Birkedal-Hansen H, Yamada S, Windsor J, Pollard AH, Lyons G, Stetler-Stevenson W, Birkedal-Hansen B, Current protocols in cell biology, Boni JS, 2008 Chapter 10:Unit 10 18
2. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. Zuo J, Ferguson TA, Hernandez YJ, Stetler-Stevenson WG, Muir D, J Neurosci 1998 18 14 5203 5211 9651203 (Pubitemid 28311937)
3. How matrix metalloproteinases regulate cell behavior. Sternlicht MD, Werb Z, Annu Rev Cell Dev Biol 2001 17 463 516 10.1146/annurev.cellbio.17.1.463 11687497 (Pubitemid 33096184)
4. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Candelario-Jalil E, Yang Y, Rosenberg GA, Neuroscience 2009 158 3 983 994 10.1016/j.neuroscience. 2008.06.025 18621108
5. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Van Wart HE, Birkedal-Hansen H, Proc Natl Acad Sci USA 1990 87 14 5578 5582 10.1073/pnas.87.14.5578 2164689 (Pubitemid 20260224)
6. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. Ogata Y, Enghild JJ, Nagase H, J Biol Chem 1992 267 6 3581 3584 1371271
7. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. O'Connell JP, Willenbrock F, Docherty AJ, Eaton D, Murphy G, J Biol Chem 1994 269 21 14967 14973 8195131 (Pubitemid 24198336)
8. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA, Science 2002 297 5584 1186 1190 10.1126/science.1073634 12183632 (Pubitemid 36193354)
9. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H, J Biol Chem 2001 276 31 29596 29602 10.1074/jbc.M102417200 11395496
10. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. Fu X, Kassim SY, Parks WC, Heinecke JW, J Biol Chem 2001 276 44 41279 41287 10.1074/jbc.M106958200 11533038
11. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GI, J Biol Chem 2002 277 18 16022 16027 10.1074/jbc.M110931200 11839746 (Pubitemid 34967885)
12. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Rosenberg GA, Lancet Neurol 2009 8 2 205 216 10.1016/S1474-4422(09) 70016-X 19161911
13. Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. Wang X, Rosell A, Lo EH, CNS Neurol Disord Drug Targets 2008 7 3 235 242 10.2174/187152708784936635 18673208
14. Multiphasic roles for matrix metalloproteinases after stroke. Rosell A, Lo EH, Curr Opin Pharmacol 2008 8 1 82 89 10.1016/j.coph.2007.12.001 18226583
15. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Candelario-Jalil E, Thompson J, Taheri S, Grossetete M, Adair JC, Edmonds E, Prestopnik J, Wills J, Rosenberg GA, Stroke 2011 42 5 1345 1350 10.1161/STROKEAHA.110.600825 21454822
16. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC, Stroke 1998 29 5 1020 1030 10.1161/01.STR.29.5.1020 9596253 (Pubitemid 28228167)
17. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A, Brain Res 2001 893 1-2 104 112 11222998 (Pubitemid 32171902)
18. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. Rosenberg GA, Navratil M, Barone F, Feuerstein G, J Cereb Blood Flow Metab 1996 16 3 360 366 8621740 (Pubitemid 26125324)
19. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Park KP, Rosell A, Foerch C, Xing C, Kim WJ, Lee S, Opdenakker G, Furie KL, Lo EH, Stroke 2009 40 8 2836 2842 10.1161/STROKEAHA.109.554824 19556529
20. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ, J Cereb Blood Flow Metab 1999 19 6 624 633 10366192 (Pubitemid 30161214)
21. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH, J Cereb Blood Flow Metab 2000 20 12 1681 1689 11129784
22. Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. Tejima E, Guo S, Murata Y, Arai K, Lok J, van Leyen K, Rosell A, Wang X, Lo EH, J Neurotrauma 2009 26 11 1935 1941 10.1089/neu.2009.0959 19469687
23. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Shigemori Y, Katayama Y, Mori T, Maeda T, Kawamata T, Acta Neurochir Suppl 2006 96 130 133 10.1007/3-211-30714-1-29 16671440
24. The role of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY, Dornbos D 3rd, Li X, Guthikonda M, J Neurosurg 2011 114 1 92 101 10.3171/2010.6.JNS10207 20617879
25. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH, J Neurosci 2000 20 18 7037 7042 10995849
26. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. Mori T, Wang X, Aoki T, Lo EH, J Neurotrauma 2002 19 11 1411 1419 10.1089/089771502320914642 12490006 (Pubitemid 35403670)
27. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, Fiebich BL, Rosenberg GA, J Pharmacol Exp Ther 2007 323 2 488 498 10.1124/jpet.107. 127035 17704356 (Pubitemid 350005134)
28. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. Meli DN, Christen S, Leib SL, J Infect Dis 2003 187 9 1411 1415 10.1086/374644 12717622 (Pubitemid 36549686)
29. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, Tauber MG, Leppert D, Brain 2001 124 Pt 9 1734 1742 11522576 (Pubitemid 32845435)
30. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH, J Neurosci 2001 21 19 7724 7732 11567062 (Pubitemid 32904971)
31. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA, J Neurosci 2005 25 27 6401 6408 10.1523/JNEUROSCI.1563-05.2005 16000631 (Pubitemid 40962536)
32. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Rosenberg GA, Estrada EY, Dencoff JE, Stroke 1998 29 10 2189 2195 10.1161/01.STR.29.10.2189 9756602 (Pubitemid 28443538)
33. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Pfefferkorn T, Rosenberg GA, Stroke 2003 34 8 2025 2030 10.1161/01.STR. 0000083051.93319.28 12855824 (Pubitemid 36944801)
34. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH, Stroke 2005 36 9 1954 1959 10.1161/01.STR.0000177517.01203.eb 16051896 (Pubitemid 41266533)
35. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J, Stroke 2001 32 8 1759 1766 10.1161/01.STR.32.8.1759 11486102 (Pubitemid 32772204)
36. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J, Stroke 2001 32 12 2762 2767 10.1161/hs1201.99512 11739970 (Pubitemid 33134461)
37. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J, Circulation 2003 107 4 598 603 10.1161/01.CIR.0000046451.38849.90 12566373 (Pubitemid 36176811)
38. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. Montaner J, Rovira A, Molina CA, Arenillas JF, Ribo M, Chacon P, Monasterio J, Alvarez-Sabin J, J Cereb Blood Flow Metab 2003 23 12 1403 1407 14663335 (Pubitemid 38018258)
39. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J, Stroke 2005 36 7 1415 1420 10.1161/01.STR.0000170641.01047.cc 15947272 (Pubitemid 40967504)
40. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J, Stroke 2008 39 4 1121 1126 10.1161/STROKEAHA.107.500868 18323498 (Pubitemid 351440679)
41. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Vukasovic I, Tesija-Kuna A, Topic E, Supanc V, Demarin V, Petrovcic M, Clin Chem Lab Med CCLM/FESCC 2006 44 4 428 434
42. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Neurology 2006 66 10 1550 1555 10.1212/01.wnl.0000216133.98416.b4 16717217 (Pubitemid 43958553)
43. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A, Stroke 2003 34 1 40 46 10.1161/01.STR.0000046764.57344.31 12515281 (Pubitemid 36070797)
44. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Stroke 2007 38 6 1855 1859 10.1161/STROKEAHA.106.481556 17478737 (Pubitemid 46847259)
45. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A, Stroke 2005 36 9 1921 1926 10.1161/01.STR.0000177870.14967.94 16100032 (Pubitemid 41266528)
46. Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. England TJ, Bath PM, Sare GM, Geeganage C, Moulin T, O'Neill D, Woimant F, Christensen H, De Deyn P, Leys D, Stroke 2010 41 12 2834 2839 10.1161/STROKEAHA.109.573063 21030711
47. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases. Quesada AR, Barbacid MM, Mira E, Fernandez-Resa P, Marquez G, Aracil M, Clin Exp Metastasis 1997 15 1 26 32 9009103 (Pubitemid 27095149)
48. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, van Mulligen T, Schulz R, Biochem Pharmacol 2009 77 5 826 834 10.1016/j.bcp.2008.11.004 19046943
49. Development of a solid-phase assay for analysis of matrix metalloproteinase activity. Lauer-Fields JL, Nagase H, Fields GB, J Biomolecular Tech JBT 2004 15 4 305 316
50. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). Nagase H, Fields CG, Fields GB, J Biol Chem 1994 269 33 20952 20957 8063713 (Pubitemid 24266460)
51. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Nagase H, Fields GB, Biopolymers 1996 40 4 399 416 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R 8765610
52. Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. Lauer-Fields JL, Sritharan T, Stack MS, Nagase H, Fields GB, J Biol Chem 2003 278 20 18140 18145 10.1074/jbc.M211330200 12642591 (Pubitemid 36799428)
53. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, Bakker AH, Biochem J 1997 323 Pt 3 603 609 9169591 (Pubitemid 27202329)
54. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen JH, Matrix Biol J Int Soc Matrix Biol 1998 17 8-9 657 665 (Pubitemid 29017232)
55. Highly sensitive FRET substrates for the assay of MMPs http://www.anaspec.com/servePdf.asp?f=c-publications24.pdf&t=publication
56. Recent advances in MMP inhibitor design. Fisher JF, Mobashery S, Cancer Metastasis Rev 2006 25 1 115 136 10.1007/s10555-006-7894-9 16680577 (Pubitemid 43723987)
57. Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Lee M, Bernardo MM, Meroueh SO, Brown S, Fridman R, Mobashery S, Org Lett 2005 7 20 4463 4465 10.1021/ol0517269 16178559 (Pubitemid 41436672)
58. Neuregulin-1 effects on endothelial and blood-brain-barrier permeability after experimental injury. Lok J, Zhao S, Leung W, Seo JH, Navaratna D, Wang X, Whalen MJ, Lo EH, Trans Stroke Res 2012 3 S1 119 S124 10.1007/s12975-012-0157-x
59. Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL, J Neurochem 2007 100 4 1108 1120 10.1111/j.1471-4159.2006.04280.x 17176264 (Pubitemid 46213933)
60. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. Zhang JW, Gottschall PE, J Neurosci Methods 1997 76 1 15 20 10.1016/S0165-0270(97)00065-4 9334934 (Pubitemid 27405081)
61. Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration. Zhang JW, Deb S, Gottschall PE, Eur J Neurosci 1998 10 11 3358 3368 10.1046/j.1460-9568.1998.00347.x 9824449 (Pubitemid 29074127)